PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
13.97%
ROE 10-15% – Moderate returns. Peter Lynch might look for growth catalysts that could push ROE higher.
-72.08%
Negative ROA indicates net losses or excessive assets. Benjamin Graham would question viability or capital misallocation.
-163.34%
Negative ROCE suggests negative EBIT or an inflated capital base. Benjamin Graham would check if the firm is structurally unprofitable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.